- Reference code :
- wf290
- Published date :
-
18 October 1999
- Expired date :
-
05 March 2027
AstraZeneca today announced that the Tel Aviv District Court has upheld the formulation patents for omeprazole. This follows an appeal by AstraZeneca and the Israeli company Unipharm. The District Court found that the inventions subject to the patents constituted a significant advance over prior art and that they were not obvious. Omeprazole is the substance used in Losec®.
Elsewhere, AstraZeneca has several pending patent infringement cases including in Germany, Australia and Denmark, which are due to be heard before the end of this year. In the US the schedule for the pre-trial proceedings, in the cases against four generic companies, has been set up to October 2000 by the District Court of Southern District of New York.
Note to News Editors: |
|
|
|
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
